Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KCNN3 | Q9UGI6 | 8/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.39 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.39 |
| ▸ | UBE2M | P61081 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460690 | 0.80 | PIK3CG (0.48) | PDE10ARAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL29869 | 0.80 | PDE10A (1.00) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL8570252 | 0.80 | PDE10A (0.56) | PDE10ARAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL30443144 | 0.77 | PDE10A (0.53) | PDE10ARAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL9301157 | 0.77 | PDE10A (0.43) | PDE10ARAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL4102510 | 0.77 | PDE10A (0.43) | PDE10ARAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL20406305 | 0.77 | PDE10A (0.43) | PDE10ARAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL10408224 | 0.77 | PDE10A (0.43) | PDE10ARAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL13022182 | 0.77 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL1018372 | 0.77 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111440174-B | Pyridine amide compound and preparation method and application thereof | 广州医科大学 | 2021-07-09 | — | — | CN | claimed |
| CN-111440174-A | Pyridine amide compound and preparation method and application thereof | 广州医科大学 | 2020-07-24 | — | — | CN | claimed |
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-12479857-B2 | Bax inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| WO-2025068090-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2025-04-03 | — | — | WO | disclosed |
| CN-118598875-A | Pyrimidine diketone amide compound and preparation method and application thereof | 广州医科大学 | 2024-09-06 | — | — | CN | disclosed |
| US-20240132506-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | Kronos Bio, Inc. (US) | 2024-04-25 | — | — | US | disclosed |
| US-11845754-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | Kronos Bio, Inc. (US) | 2023-12-19 | — | — | US | disclosed |
| CN-112996790-B | Compounds, compositions and methods for modulating CDK9 activity | 克洛诺斯生物公司 | 2023-11-03 | — | — | CN | disclosed |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| EP-0591528-B1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME | OTSUKA PHARMA CO LTD (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5843951-A | Analgesic composition of pyrazolo(1,5-A) pyrimidines | OTSUKA PHARMACEUTICAL FACTORY INC. (JP) | 1998-12-01 | — | — | US | disclosed |
| US-5688949-A | CYCLOOXYGENASE INHIBITORS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1997-11-18 | — | — | US | disclosed |
| EP-0795555-A1 | ANALGESICS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1997-09-17 | — | — | EP | disclosed |
| US-5602137-A | Pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF-LILLY GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5602136-A | Pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF-LILLY GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5571813-A | Fused pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF-LILLY GMBH (DE) | 1996-11-05 | — | — | US | disclosed |
| EP-0628559-A1 | Pyrimidine compounds and their use as pharmaceuticals | Beiersdorf-Lilly GmbH (DE) | 1994-12-14 | — | — | EP | disclosed |
| EP-0591528-A1 | PYRAZOLO 1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1994-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | BAX, BCL2, BAK1 | PDE10A 4243/4885RAB9A 2006/4885MAPT 3029/4885 |
| US-20240132506-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CDK9 ACTIVITY | CDK9, CDK19, CDK7 | PDE10A 698/4885RAB9A 204/4885MAPT 2395/4885 |
| US-11845754-B2 | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity | CDK9, CDK19, CDK7 | PDE10A 929/4885RAB9A 300/4885MAPT 2706/4885 |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | GLA, BACE1, GAA | PDE10A 2783/4885RAB9A 983/4885MAPT 21/4885 |
| US-12479857-B2 | Bax inhibitors and uses thereof | BAX, TMBIM6, BCL2 | PDE10A 3700/4885RAB9A 1715/4885MAPT 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.